Therapeutic Drugs for Autoimmune Diseases Continue to Shine as Companies Cope with Generics
May 1, 2012 - 4:58:19 PM
Greystone Associates Analyzes the Current Treatment Landscape and Assesses Pipeline Prospects
(HealthNewsDigest.com) - Amherst, NH) – Autoimmune diseases, a group of chronic ailments that includes arthritis, psoriasis, lupus, and multiple sclerosis, afflict tens of millions of people worldwide and result in levels of morbidity that can significantly impact quality of life and longevity. They represent some of the most difficult therapeutic challenges facing the healthcare community. The refractory nature of this family of diseases is rooted in the complexities and genetic underpinnings of the human immune response, resulting in a set of disease targets that are at once physiologically ubiquitous and highly individualized.
This historically bleak therapeutic picture is now changing. The availability of analytical techniques capable of elucidating the intricacies of the immune cascade has led to the identification of a large and growing list of potential targets for modulating the mechanisms of autoimmunity for a number of known conditions. This knowledge has led to the development of biological drugs that have brought a measure of relief to many autoimmune patients and hope to the remainder.
In spite of recent progress, autoimmune diseases continue to represent an area of significant unmet need. Several autoimmune disorders such as lupus have yet to benefit from the current wave of biologicals. Side effects and safety profiles remain serious concerns and therapeutic limitations.
These challenges extend to the development process itself and can be formidable. Inclusion and exclusion criteria for clinical trial recruitment must be carefully designed to avoid excessive heterogeneity in the treatment population. The frequent unavailability of quantitative endpoints and relatively low patient retention rates and compliance levels add further risk. But the commercial opportunities represented by this market continue to draw interest. More than a dozen potentially important candidates are currently winding their way through the development process.
A new research study, Autoimmune Disease Therapeutics to 2016: Targets, Technologies, Therapies, Markets and Opportunities, examines the current therapeutic landscape for six major autoimmune diseases, and analyzes key late-stage candidates and their probable impact on treatment strategies and prescribing trends. It also identifies the key players in each therapeutic segment, describes the regulatory and commercial environment, and assesses the dynamics of patient care that will affect market development. The report includes forecasts by segment, indication and drug class.
More information is available at www.greystoneassociates.org .
Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Source: Greystone Research Associates
P.O. Box 1362 603-595-4340 fax 603-218-7020 firstname.lastname@example.org
© Copyright by HealthNewsDigest.com